What is the 13F Pro Quality Score for NXL?

13F Pro ranks Nexalin Technology, Inc. (NXL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NXL's current score at https://13fpro.ai/research/NXL (free sign-up required for the full ranking).

Which hedge funds own the most NXL stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of NXL include PEAK6, GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/NXL as soon as new 13F filings post.

Where does 13F Pro source NXL data?

All Nexalin Technology, Inc. fundamentals and ownership data come directly from SEC EDGAR. Nexalin Technology, Inc. files with the SEC under CIK 1527352. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NXL in?

Nexalin Technology, Inc. (NXL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NXL research updated on 13F Pro?

NXL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Nexalin Technology, Inc.(NXL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1527352 NXL stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $1.3M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

NXL Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Nexalin Technology, Inc. (NXL), a Healthcare sector company. NXL is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $1.3m in revenue. Based on the latest XBRL financial filings (Q1 2026), Nexalin Technology, Inc. reports quarterly revenue of $14.9K, net income of $-2.1M, free cash flow of $-1.7M. Top institutional holders of NXL by reported 13-F value include PEAK6, GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. NXL trades on the Nasdaq exchange and files with the SEC under CIK 1527352. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NXL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Nexalin Technology, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$14.9K

Net Income

Q1 2026

$-2.1M

Free Cash Flow

Q1 2026

$-1.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-87.2% YoY

$168.7KFY 2024

FY21 $144.1KFY22 $1.3MFY24 $168.7K

Net Income

-348.1% YoY

$-7.6MFY 2024

FY21 $-6.1MFY22 $-1.7MFY24 $-7.6M

Operating Income

-323.1% YoY

$-7.8MFY 2024

FY21 $-6.0MFY22 $-1.8MFY24 $-7.8M

EPS (Diluted)

-176.7% YoY

$-0.83FY 2024

FY21 —FY22 $-0.30FY24 $-0.83

Total Assets

-43.2% YoY

$4.2MFY 2024

FY21 $753.7KFY22 $7.4MFY24 $4.2M

Op. Cash Flow

-78.0% YoY

$-3.9MFY 2024

FY21 $-1.1MFY22 $-2.2MFY24 $-3.9M

Metric	FY 2024	FY 2022	FY 2021
Revenue	$168.7K -87.2%	$1.3M +817.2%	$144.1K
Net Income	$-7.6M -348.1%	$-1.7M +72.1%	$-6.1M
Operating Income	$-7.8M -323.1%	$-1.8M +69.5%	$-6.0M
EPS (Diluted)	$-0.83 -176.7%	$-0.30	—
Total Assets	$4.2M -43.2%	$7.4M +886.1%	$753.7K
Operating Cash Flow	$-3.9M -78.0%	$-2.2M -105.8%	$-1.1M

AI Insight: NXL Financial Trends

Nexalin has generated zero revenue for eight consecutive quarters while burning cash every period — no commercial inflection yet visible.

• Revenue has been $0M across all eight quarters from Q2 2024 through Q1 2026, indicating no commercial product sales.

• Net losses stabilized around $-2M per quarter from Q1 2025 onward, down from a peak of $-3M in Q4 2024.

• Equity fluctuated between $1M and $6M, ending Q1 2026 at $3M — reflecting periodic capital raises offsetting ongoing losses.

⚠ Operating cash outflow doubled to $-2M in Q1 2026 — first acceleration in burn rate in over a year.

⚠ Equity of $3M in Q1 2026 against persistent $-2M quarterly losses implies runway of roughly one to two quarters without new capital.

AI Insight: NXL Ratio Trends

Data too sparse to establish meaningful trends — only two ROE/ROA readings available across nine reported periods.

• ROE was -197.5% in Q3 2024, narrowed to -106.0% in Q2 2025, then deteriorated sharply back to -190.9% in Q3 2025.

• ROA of -96.3% was recorded only once, in Q2 2025; all other periods lack sufficient data for comparison.

⚠ ROE swung from -106.0% to -190.9% in a single quarter — deep, volatile losses signal persistent equity erosion.

⚠ OpMargin, NPM, ROIC, and D/E are entirely absent — inability to assess leverage or profitability is a material blind spot.

Get alerted when NXL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Nexalin Technology, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NXL

PEAK6 LLC
$133.9K384,460 sh
GEODE CAPITAL MANAGEMENT, LLC
$86.0K247,037 sh
VANGUARD CAPITAL MANAGEMENT LLC
$44.0K126,536 sh
VANGUARD FIDUCIARY TRUST CO
$17.9K51,386 sh
STATE STREET CORP
$11.3K32,300 sh
NORTHERN TRUST CORP
$8.4K24,100 sh
Kovack Advisors, Inc.
$8.2K23,325 sh
StoneX Group Inc.
$8.0K22,923 sh
UBS Group AG
$7.7K22,189 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$7.3K20,928 sh

Fund	Value	Shares
PEAK6 LLC	$133.9K	384,460
GEODE CAPITAL MANAGEMENT, LLC	$86.0K	247,037
VANGUARD CAPITAL MANAGEMENT LLC	$44.0K	126,536
VANGUARD FIDUCIARY TRUST CO	$17.9K	51,386
STATE STREET CORP	$11.3K	32,300
NORTHERN TRUST CORP	$8.4K	24,100
Kovack Advisors, Inc.	$8.2K	23,325
StoneX Group Inc.	$8.0K	22,923
UBS Group AG	$7.7K	22,189
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$7.3K	20,928

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NXL on your watchlist

Track score changes the day Nexalin Technology, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NXL a good stock to buy?

13F Pro's AI-powered analysis of Nexalin Technology, Inc. (NXL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NXL are available on the NXL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NXL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NXL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Nexalin Technology, Inc.'s investment landscape.